Rett Syndrome

None approved; multiple ASO programs in preclinical/early clinical stages

Rett syndrome is a severe neurodevelopmental disorder that primarily affects girls. It is caused by loss-of-function mutations in the MECP2 gene on the X chromosome, which encodes methyl-CpG binding protein 2 — a protein that plays a critical role in regulating gene expression in the brain, particularly in mature neurons. Rett syndrome is one of the most common genetic causes of severe intellectual disability in females.

The disease typically follows a distinctive course: apparently normal development for the first 6–18 months, followed by a period of rapid regression characterized by loss of acquired hand skills and spoken language, development of stereotypic hand movements (wringing, squeezing, clapping), gait abnormalities, and social withdrawal. Additional features include seizures, breathing irregularities (hyperventilation, breath-holding, aerophagia), scoliosis, and growth retardation.

MECP2 is X-linked, and the disease mechanism is complex. In girls (XX), X-inactivation means that in any given cell, either the maternal or paternal X chromosome is active. In Rett syndrome, roughly half of neurons express the normal MECP2 allele and half express the mutant allele (or no MECP2 if the mutation is a deletion). The mosaic nature of X-inactivation means that restoring MECP2 function to the cells expressing the mutant allele could be therapeutic, but overexpression of MECP2 is also toxic — MECP2 duplication syndrome causes a distinct but equally severe neurological disorder in males.

This dosage sensitivity makes ASO therapy for Rett syndrome particularly nuanced. The goal is not simply to increase or decrease MECP2 expression, but to fine-tune it. Several ASO strategies are being explored in preclinical research: targeting the X-inactivation mechanism to reactivate the silenced normal allele in cells that are expressing the mutant copy, or modulating MECP2 transcript processing to optimize protein levels.

The challenge of MECP2 dosage sensitivity means that any therapeutic approach must carefully calibrate gene expression — too little MECP2 causes Rett syndrome, and too much causes MECP2 duplication syndrome. ASOs offer an advantage over gene therapy in this regard because their effects are reversible and dose-adjustable. ASO dosing can be titrated over time, and treatment can be discontinued if adverse effects are observed, providing a level of control that permanent genetic modifications do not.

Pequliar designs ASO candidates for Rett syndrome based on the patient’s specific MECP2 mutation and the therapeutic strategy appropriate for their case. The platform scores candidates for binding affinity, structural accessibility, and off-target safety, providing synthesis-ready sequences for preclinical evaluation. Given the dosage sensitivity of MECP2, careful experimental validation is essential before any clinical application.

Design an ASO for Rett Syndrome

Describe your mutation and get ranked, synthesis-ready ASO candidates in minutes. $399 per design.

Pequliar is a computational research tool for informational purposes only. All sequences are computationally predicted candidates that have not been experimentally validated. Pequliar does not prescribe, recommend, or administer any compound. Independent validation by qualified professionals is required.